- Bing Wang Ph.D.
- Aleksander S. Popel Ph.D.
An additional fee is required to attend this workshop. To register, visit www.aaps.org/AMRegister
Immune responses directed against tumors are one of the body’s natural defenses against the growth and proliferation of cancer cells. However, over time and under pressure from immune attack, cancers develop strategies to evade immune-mediated killing allowing them to develop unchecked. Antibodies targeting immune checkpoints such as CTLA-4, PD-1, and PD-L1 have demonstrated efficacy in cancer treatment, although the activity was modest for poorly immunogenic tumors and benefited only a subset of patients in clinic. The conventional pharmacokinetic exposure-response relationship concept may not be readily applicable for cancer immunotherapies.
This workshop focuses on the utilization of systems, agent-based, translational, and population modeling approaches to quantitatively describe the key components of the immune system, its interactions with immune checkpoint modulators and cancer cells, and clinical treatment response. In addition, evaluations of potential factors (predictors) of clinical response and combination therapies via various modeling approaches will be discussed.